Article

Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers

Jennifer Lloyd

Nazy Zomorodian

Geeta Devgan

Julia Batten

talazoparib, enzalutamide, mCRPC, treatment management, adverse events
CJON 2024, 28(5), 483-491. DOI: 10.1188/24.CJON.483-491

Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).

Objectives: This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.

Methods: This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.

Findings: Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.

Members Only
Not a current ONS member or journal subscriber?

Become a Member

Explore the benefits of membership.
Join ONS or Renew Membership

Purchase This Article

Receive a PDF to download and print.